- Home
- TXMD vs CANF Comparison
TXMD vs CANF Comparison
Compare TXMD & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- CANF
- Stock Information
- Founded
- TXMD 2008
- CANF 1994
- Country
- TXMD United States
- CANF Israel
- Employees
- TXMD N/A
- CANF N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- CANF Health Care
- Exchange
- TXMD Nasdaq
- CANF Nasdaq
- Market Cap
- TXMD 13.5M
- CANF 13.5M
- IPO Year
- TXMD N/A
- CANF N/A
- Fundamental
- Price
- TXMD $1.14
- CANF $1.03
- Analyst Decision
- TXMD
- CANF Strong Buy
- Analyst Count
- TXMD 0
- CANF 2
- Target Price
- TXMD N/A
- CANF $14.00
- AVG Volume (30 Days)
- TXMD 30.4K
- CANF 83.3K
- Earning Date
- TXMD 07-30-2025
- CANF 08-29-2025
- Dividend Yield
- TXMD N/A
- CANF N/A
- EPS Growth
- TXMD N/A
- CANF N/A
- EPS
- TXMD N/A
- CANF N/A
- Revenue
- TXMD $1,841,000.00
- CANF $674,000.00
- Revenue This Year
- TXMD $427.09
- CANF $461.72
- Revenue Next Year
- TXMD N/A
- CANF N/A
- P/E Ratio
- TXMD N/A
- CANF N/A
- Revenue Growth
- TXMD 53.55
- CANF N/A
- 52 Week Low
- TXMD $0.70
- CANF $0.98
- 52 Week High
- TXMD $2.44
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- TXMD 43.84
- CANF 42.43
- Support Level
- TXMD $1.07
- CANF $1.00
- Resistance Level
- TXMD $1.24
- CANF $1.05
- Average True Range (ATR)
- TXMD 0.08
- CANF 0.02
- MACD
- TXMD 0.00
- CANF 0.00
- Stochastic Oscillator
- TXMD 59.62
- CANF 40.00
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).